<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638258</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ-151-201</org_study_id>
    <nct_id>NCT03638258</nct_id>
  </id_info>
  <brief_title>The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis</brief_title>
  <acronym>ARQ-151-201</acronym>
  <official_title>A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcutis Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcutis Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.3%
      or ARQ-151 cream 0.15% or vehicle cream is applied once daily for 84 days to subjects with
      chronic plaque psoriasis involving between 2 and 20% body surface area.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Actual">May 29, 2019</completion_date>
  <primary_completion_date type="Actual">May 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel group, double blind, vehicle-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>ARQ-151 drug product will be supplied as a 0.3% and 0.15% cream. The matching vehicle cream will contain only excipients of ARQ-151 cream.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>An Investigator Global Assessment (IGA) score of 'clear' or 'almost clear'</measure>
    <time_frame>Week 6</time_frame>
    <description>Primary Efficacy Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA score of 'clear' or 'almost clear'</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in Modified Psoriasis Area Severity</measure>
    <time_frame>Weeks 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in percent body surface area affected</measure>
    <time_frame>Weeks 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA score of 'clear' or 'almost clear' plus a 2-grade improvement</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects with intertriginous area involvement, and with severity of the intertriginous lesions at least 'mild' (intertriginous IGA (I-IGA) ≥2) at Baseline, 'I-IGA' score of 'clear' or 'almost clear'</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Worst Itch-Numeric (WI-NRS) Rating Scale pruritus score</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In subjects with WI-NRS pruritus score ≥ 6 at baseline, a 4-point reduction in WI-NRS pruritus score</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Psoriasis Area Severity Index-75 (mPASI-75; subjects who achieve a 75% reduction in mPASI from Baseline) improvement</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Psoriasis Area Severity Index-90 (mPASI-90; subjects who achieve a 90% reduction in mPASI from Baseline) improvement</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Symptom Diary (PSD) improvement</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Itch-related Sleep Loss NRS (Numeric Rating Scale) score</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Dermatology Life Quality Index (DLQI) score</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to the questions of PSD analyzed as improvement</measure>
    <time_frame>Weeks 4, 6, 8 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARQ-151 cream 0.3% topically applied once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-151 cream 0.15%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARQ-151 cream 0.15% topically applied once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARQ-151 Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching vehicle cream containing only excipients of ARQ-151 cream applied once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 Cream 0.3%</intervention_name>
    <description>Applied once daily for 12 weeks</description>
    <arm_group_label>ARQ-151 cream 0.3%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 Cream 0.15%</intervention_name>
    <description>Applied once daily for 12 weeks</description>
    <arm_group_label>ARQ-151 cream 0.15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ-151 vehicle cream</intervention_name>
    <description>Applied once daily for 12 weeks</description>
    <arm_group_label>ARQ-151 Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants legally competent to sign and give informed consent

          -  Males and females ages 18 years and older (inclusive)

          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined
             by the Investigator

          -  Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at
             Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must
             agree to use at least one form of highly effective contraception throughout the trial.

          -  In good health as judged by the Investigator, based on medical history, physical
             examination, serum chemistry labs, hematology values, and urinalysis.

          -  Subjects are considered reliable and capable of adhering to the Protocol and visit
             schedule, according to the judgment of the Investigator.

        Exclusion Criteria:

          -  Planned excessive exposure of treated area(s) to either natural or artificial sunlight
             or tanning bed.

          -  Females who are pregnant, wishing to become pregnant during the study, or are
             breast-feeding.

          -  Previous treatment with ARQ-151 or its active ingredient

          -  Subjects with any serious medical condition or laboratory abnormality that would
             prevent study participation or place the subject at significant risk, as determined by
             the Investigator.

          -  Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation
             of study medication.

          -  Subjects who are unable to communicate, read or understand the local language, or who
             display another condition, which in the Investigator's opinion, makes them unsuitable
             for clinical study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Welgus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Arcutis Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcutis Clinical Site 35</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 29</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 28</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 27</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 12</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 16</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 21</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 34</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 33</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 20</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 22</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 14</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 39</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 15</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 19</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 37</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 13</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 23</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 24</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 31</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 18</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 11</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 38</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 10</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 25</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 26</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 32</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 17</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 30</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcutis Clinical Site 36</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

